You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Adult AML

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed Adult ALL, Relapsed Adult AML Trial in Changchun (Plerixafor)

Active, not recruiting
  • Relapsed Adult ALL
  • Relapsed Adult AML
  • Changchun, Jilin, China
    First Hospital of Jilin University
Nov 19, 2023

Adult Acute Myeloid Leukemia Trial (mocravimod)

Not yet recruiting
  • Adult Acute Myeloid Leukemia
  • (no location specified)
Jun 27, 2022

Acute Myeloid Leukemia Trial (ABBV-787)

Not yet recruiting
  • Acute Myeloid Leukemia
  • (no location specified)
Sep 29, 2023

Acute Myeloid Leukemia, Relapsed Adult AML Trial (Lintuzumab-Ac225, Venetoclax, Azacitidine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Relapsed Adult AML
  • Lintuzumab-Ac225
  • +2 more
  • (no location specified)
Feb 22, 2022

AML, Adult, Minimal Residual Disease Trial in Guangzhou (chidamide and azacitidine)

Not yet recruiting
  • AML, Adult
  • Minimal Residual Disease
  • chidamide and azacitidine
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Sep 27, 2023

AML, Adult Trial (Biological characterization of AML with MECOM or atypical 3q26 rearrangements)

Not yet recruiting
  • AML, Adult
  • Biological characterization of AML with MECOM or atypical 3q26 rearrangements
  • (no location specified)
Apr 21, 2023

AML, Adult, Refractory AML, Relapsed Adult AML Trial in France (AzaCITIDine Oral Tablet, Xospata)

Not yet recruiting
  • AML, Adult
  • +4 more
  • Amiens, France
  • +19 more
Sep 1, 2023

Leukemia, Myeloid, Acute, Relapsed Adult AML, Refractory Leukemia Trial in Xiamen (venetoclax combining chidamide and

Recruiting
  • Leukemia, Myeloid, Acute
  • +2 more
  • venetoclax combining chidamide and azacitidine (VCA)
  • Xiamen, Fujian, China
    Bing Xu
Aug 1, 2022

AML, Adult Trial (Pharmacoscopy, Clinical standard-of-care (physician's choice))

Not yet recruiting
  • AML, Adult
  • Pharmacoscopy
  • Clinical standard-of-care (physician's choice)
  • (no location specified)
Nov 20, 2023

Assessment of Geriatric Evaluations Impact on New AML Guidance

Not yet recruiting
  • AML, Adult
    • Philadelphia, Pennsylvania
      Abramson Cancer Center at University of Pennsylvania
    Jun 12, 2023

    AML, Adult Trial (STI-8591)

    Not yet recruiting
    • AML, Adult
    • (no location specified)
    Jul 12, 2023

    Acute Myeloid Leukemia (AML), Multiple Myeloma (MM) Trial (3x10(6) CART-38 cellls, 7x10(5) CART-38 cells, 7x10(6) CART-38 cells)

    Not yet recruiting
    • Acute Myeloid Leukemia (AML)
    • Multiple Myeloma (MM)
    • 3x10(6) CART-38 cellls
    • +5 more
    • (no location specified)
    Jul 15, 2022

    Relapsed Adult AML Trial in Germany (Venetoclax Oral Tablet)

    Recruiting
    • Relapsed Adult AML
    • Refractory AML
    • Venetoclax Oral Tablet
    • Augsburg, Germany
    • +11 more
    Jan 11, 2023

    Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in

    Not yet recruiting
    • Acute Myeloid Leukemia
      • (no location specified)
      Sep 22, 2023

      Relapsed Adult AML, Refractory AML Trial in Milwaukee (Navitoclax Dose Level -1, Navitoclax Dose Level 0, Navitoclax Dose Level

      Not yet recruiting
      • Relapsed Adult AML
      • Refractory AML
      • Navitoclax Dose Level -1
      • +10 more
      • Milwaukee, Wisconsin
        Froedtert Hospital & the Medical College of Wisconsin
      Aug 17, 2023

      Acute Myeloid Leukemia (AML) Trial in Austria, Italy, Spain (Ivosidenib Oral Tablet, Azacitidine)

      Not yet recruiting
      • Acute Myeloid Leukemia (AML)
      • Vienna, Austria
      • +3 more
      Jun 8, 2023

      AML, Adult Trial in Netherlands (azacitidine, Venetoclax, Cobicistat)

      Not yet recruiting
      • AML, Adult
      • Amersfoort, Netherlands
      • +17 more
      Aug 23, 2023

      AML, Adult, Minimal Residual Disease Trial (MRD assessment)

      Not yet recruiting
      • AML, Adult
      • Minimal Residual Disease
      • MRD assessment
      • (no location specified)
      Oct 13, 2023

      NHL, Adult, AML, Adult Recurrent Trial in Zhengzhou, Tianjin (ETH-155008)

      Recruiting
      • NHL, Adult
      • AML, Adult Recurrent
      • Zhengzhou, Henan, China
      • +1 more
      Feb 24, 2023

      AML, Adult, Minimal Residual Disease Trial in Tianjin (CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine)

      Not yet recruiting
      • AML, Adult
      • Minimal Residual Disease
      • CD33/CLL1 dual CAR-NK cell
      • +5 more
      • Tianjin, China
        Institute of Hematology & Blood Diseases Hospital
      Aug 4, 2023

      Acute Myeloid Leukemia, Relapsed Adult AML Trial in United States (Lintuzumab-Ac225, Venetoclax, Spironolactone)

      Recruiting
      • Acute Myeloid Leukemia
      • Relapsed Adult AML
      • Lintuzumab-Ac225
      • +2 more
      • Los Angeles, California
      • +4 more
      Feb 22, 2022

      AML, Adult Trial in Hangzhou (CLL1 CAR-NK cell injection)

      Recruiting
      • AML, Adult
      • CLL1 CAR-NK cell injection
      • Hangzhou, Zhejiang, China
        Clinical research ethics committee of the first affiliated hospi
      Aug 30, 2023

      Acute Myeloid Leukemia Trial in Suzhou (Venetoclax Oral Tablet, Daunorubicin)

      Recruiting
      • Acute Myeloid Leukemia
      • Suzhou, Jiangsu, China
      • +1 more
      Jul 3, 2023

      AML, Adult Trial in Hangzhou (QN-030a, Cyclophosphamid, Fludarabine)

      Recruiting
      • AML, Adult
      • Hangzhou, Zhejiang, China
        The first affiliated hospital of medical college of zhejiang uni
      Dec 29, 2022

      AML, Adult Trial in Berne (HDM201, Midostaurin)

      Terminated
      • AML, Adult
      • Berne, Switzerland
        Departement of Medical Oncology, University Hospital Berne
      Oct 3, 2022